Celcuity Inc.
NASDAQ · us_market
No AI summary generated yet for this ticker.
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.
Vericel develops cell therapies for cartilage repair and burn care, serving hospitals and clinics across the United States.
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price target from $165 to $185.
Corvus Pharmaceuticals develops immuno-oncology therapies, advancing clinical candidates for cancer and immune-related conditions.
Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust clinical pipeline.
Celcuity (CELC) is back in focus after reporting pivotal Phase 3 VIKTORIA-1 data for gedatolisib in HR-positive, HER2-negative advanced breast cancer, expanding the VIKTORIA-2 program and preparing for a potential FDA decision. See our latest analysis for Celcuity. The recent VIKTORIA-1 data, VIKTORIA-2 expansion and preparations for a potential FDA decision have been reflected in strong momentum, with an 11.51% 1 month share price return and a very large 1 year total shareholder return,...
Celcuity expands VIKTORIA-2 to endocrine-sensitive breast cancer patients and advances injectable gedatolisib formulation.
Wells Fargo analyst Eva Fortea Verdejo maintains Celcuity (NASDAQ:CELC) with a Overweight and raises the price target from $150 to $183.
Needham analyst Gil Blum reiterates Celcuity (NASDAQ:CELC) with a Buy and maintains $157 price target.
Celcuity Inc (CELC) reports significant progress in clinical trials and strategic preparations for a potential drug launch, despite facing increased financial losses and operational expenses.
Celcuity (NASDAQ:CELC) reported a wider first-quarter loss as the biotechnology company increased spending tied to commercial launch preparations and continued development of gedatolisib, its investigational therapy for hormone receptor-positive, HER2-negative advanced breast cancer. On the company
Jodi Sievers: Thank you, Matthew, and good afternoon, everyone. Thank you for joining us to review Celcuity's first quarter 26 financial results and business update. Earlier today, Celcuity released for the first quarter ended 03/31/2026.
Celcuity (CELC) Q1 loss of -$0.97 beat estimates by 9.7%, with $0 revenue. Shares fell 3.8% post-market despite positive Phase 3 VIKTORIA-1 trial data in breast cancer.
Celcuity Inc. (CELC) Q1 2026 Earnings Call May 14, 2026 4:30 PM EDTCompany ParticipantsJodi Sievers - Head of Investor Relations & Corporate...
Celcuity (NASDAQ:CELC) reported quarterly losses of $(0.86) per share which beat the analyst consensus estimate of $(1.05) by 18.1 percent. This is a 6.17 percent decrease over losses of $(0.81) per share from the same
Phase 3 VIKTORIA-1 trial achieved primary endpoint with clinically meaningful improvement in progression-free survival in PIK3CA mutant cohort; detailed data for gedatolisib regimens will be...
Celcuity Inc: Celcuity's phase 3 VIKTORIA-2 trial of gedatolisib as a first-line treatment for HR+/HER2- advanced breast cancer expanding to include endocrine-sensitive patients Celcuity Inc -...
Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced updates to the Phase 3
MINNEAPOLIS, May 14, 2026 -- Celcuity Inc. , a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today...
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 1.52M | $173.34M | 0.01% | Trimmed-7.3% | 2026-03-31 |
| Wellington | fundamental | 429.0K | $48.96M | 0.01% | Added+15.6% | 2026-03-31 |
| Citadel | multi-strat | 280.3K | $32.00M | 0.04% | New | 2026-03-31 |
| FidelityFMR | fundamental | 36.4K | $4.15M | 0.00% | Added+36.4% | 2026-03-31 |
| DEShaw | quant | 20.7K | $2.36M | 0.00% | Trimmed-64.1% | 2026-03-31 |
| TRowePrice | fundamental | 1.28M | $146.08K | 0.02% | Added+3.2% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-13upcoming | -0.98 | — | — |
| 2026-05-14 | -1.06 | -0.97 | +8.80% |
| 2026-03-25 | -1.01 | -0.73 | +27.72% |
| 2025-11-12 | -0.96 | -0.78 | +18.47% |
| 2025-08-14 | -0.84 | -0.93 | -10.06% |
| 2025-05-14 | -0.86 | -0.81 | +5.81% |
| 2025-03-31 | -0.67 | -0.75 | -11.94% |
| 2024-11-14 | -0.70 | -0.65 | +7.14% |
| 2024-08-14 | -0.55 | -0.58 | -5.45% |
| 2024-05-15 | -0.70 | -0.64 | +8.31% |
| 2024-03-27 | -0.75 | -0.61 | +18.67% |
| 2023-11-13 | -0.53 | -0.78 | -47.17% |
| 2023-08-10 | -0.46 | -0.58 | -26.09% |
| 2023-05-15 | -0.43 | -0.47 | -9.30% |
| 2023-03-23 | -0.31 | -0.60 | -93.55% |
| 2022-11-10 | -0.60 | -0.75 | -25.00% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| CELC | +5.75% | +23.72% | +33.23% | +1150.05% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +2.78% | +28.36% | +36.67% | +1137.36% |